Tysabri and PML: What Ohio Patients Should Know

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

Legacy of Health Information and the Shift to Legal Context

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This serious brain infection, though rare, has been associated with the medication. Building on a tradition of transparent risk communication, this page provides a factual overview of Tysabri-related PML, including risk factors, symptoms, and FDA warnings, to help you have an informed discussion with your healthcare provider.

Medical Evidence and Risk Factors for Tysabri-Associated PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Ohio who have developed PML after Tysabri treatment, understanding the medical evidence, risk factors, and legal considerations—including the statute of limitations—is essential. The prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical data and postmarketing surveillance. Three primary risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy, and the expected benefit must be weighed against the PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus, which typically remains latent in immunocompetent individuals. In patients receiving Tysabri, the drug's mechanism—blocking alpha-4 integrin-mediated adhesion of leukocytes to endothelial cells—impairs immune surveillance in the central nervous system. This allows JC virus reactivation and lytic infection of oligodendrocytes, leading to demyelination and progressive neurological deficits. Clinical presentation of PML can include cognitive decline, motor weakness, visual disturbances, and speech difficulties. Diagnosis is confirmed by MRI findings and detection of JC virus DNA in cerebrospinal fluid via PCR. The disease usually leads to severe disability or death, as noted in the boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Regulatory Framework and Risk Mitigation

The FDA requires that Tysabri be prescribed only through the TOUCH Prescribing Program, a restricted distribution program designed to mitigate PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must be enrolled, read the Medication Guide, understand the risks, and sign a Patient Enrollment Form. Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these precautions, PML cases have continued to occur, raising questions about the adequacy of warnings and the effectiveness of risk mitigation strategies. For affected patients in Ohio, settlement-related considerations involve the timeline between Tysabri exposure and documented harm. PML can develop months to years after starting Tysabri, with risk increasing with longer treatment duration (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The statute of limitations for product liability claims in Ohio is generally two years from the date the injury was discovered or should have been discovered. Given the insidious onset of PML symptoms, the discovery date may be when a definitive diagnosis is made. Patients and their families should document the date of first symptoms, diagnosis, and any communications with healthcare providers regarding Tysabri risks.

Legal Considerations and Settlement Factors in Ohio

The adequacy of warnings is a central issue in potential settlements. The boxed warning clearly states the PML risk and identifies risk factors, but some plaintiffs may argue that the warnings were insufficient or that the TOUCH program did not adequately prevent harm. Evidence from the prescribing information indicates that Tysabri "should not be used in combination with immunosuppressants or inhibitors of TNF-α" in Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), and that prior immunosuppressant use is a risk factor for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These details may inform arguments about whether the drug's labeling adequately communicated the cumulative risk. Settlement amounts for Tysabri-related PML cases have varied based on factors such as the severity of disability, medical expenses, lost income, and the strength of evidence regarding warning adequacy. In Ohio, plaintiffs must also consider whether the manufacturer, Biogen, provided adequate post-marketing surveillance and risk communication. The timeline between exposure and harm is critical: patients who developed PML after prolonged Tysabri use (e.g., beyond two years) may have stronger claims, as the risk was known and should have prompted more frequent monitoring or discontinuation. In summary, Tysabri-associated PML is a severe, often fatal condition with well-documented risk factors. Ohio patients affected by PML should be aware of the statute of limitations, which typically runs from the date of diagnosis. The adequacy of warnings, the role of the TOUCH program, and the timing of harm relative to treatment duration are key elements in evaluating potential settlement claims. Legal counsel with expertise in pharmaceutical liability should be consulted to assess individual circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Ohio?

In Ohio, the statute of limitations for product liability claims is generally two years from the date the injury was discovered or should have been discovered. For PML, this is typically the date of definitive diagnosis. It is crucial to document the onset of symptoms and diagnosis to preserve the claim.

What are the main risk factors for developing PML while on Tysabri?

The three primary risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are identified in the prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.